Kratom Addiction Treatment Options in Kansas

Something shifted in Kansas this year, and if you’re reading this because kratom has become a bigger part of your life than you meant it to, you’re not imagining it. In 2026, state lawmakers introduced SB 497, a bill to add kratom to Schedule I of the Kansas Uniform Controlled Substances Act ¹⁴. It was vetoed. Two years earlier, HB 2188 had tried a different path, treating kratom as a consumer product that needed licensing, adulteration limits, and an age restriction on sales ¹⁵. Neither approach settled the question. What they did was pull kratom out of the gray zone it had lived in for years and put it squarely on the table.

At the same time, the clinical picture got clearer. Peer-reviewed reviews now describe kratom withdrawal as looking a lot like opioid withdrawal, and researchers are openly saying there are still no formal treatment guidelines for kratom use disorder ^{3, 8}. That gap sounds scary, but it’s actually useful information. It means anyone telling you they have a proprietary kratom cure isn’t being straight with you. It also means the care that does work, when it works, borrows from decades of opioid-treatment experience rather than starting from scratch.

You’re walking into a moment where Kansas is finally paying attention, the science is catching up, and the honest answers are more available than they were even a year ago. That’s actually good news for you.

If it feels like more people around you are quietly struggling with kratom, the numbers back up what you’re sensing. U.S. poison centers logged 14,449 kratom exposure reports between 2015 and 2025, and the single year of 2025 alone accounted for 3,434 of them — roughly a 1,200% jump from the 263 reports recorded in 2015 ^{10, 11}. That’s a decade-long climb that turned into a near-vertical line in the last stretch. Not every one of those calls is a person in your exact situation, and poison-center data captures exposure events rather than confirmed diagnoses. Still, the direction is unmistakable, and Kansas isn’t sitting outside that curve.

Here’s what that pattern actually means for someone standing where you are: more people are showing up in emergency rooms, more clinicians are being asked what to do, and more families are quietly Googling the same phrases you probably typed to land here. You’re not the outlier. You’re part of a wave that public-health officials only recently started counting properly.

The FDA has documented that kratom users can meet clinical criteria for substance use disorder — tolerance, cravings, using more than intended, withdrawal when they stop ¹. That’s not opinion. That’s the same diagnostic framework used for every other substance. If you’ve been telling yourself this is a habit, or a supplement issue, or something you can white-knuckle through, the evidence disagrees with you gently. And gently is the right word, because there’s no shame in the diagnosis. There’s just a name for what you’ve been fighting alone.

Let’s be straight with each other about medications, because this is where a lot of websites overpromise. There is no FDA-approved medication specifically for kratom use disorder. Researchers writing in the peer-reviewed literature say it plainly: no formal guidelines exist yet ⁸. Anyone marketing a kratom-specific cure is getting ahead of the evidence.

What does exist is a growing stack of case reports and small case series pointing in the same direction. Sublingual buprenorphine/naloxone — you may know it as Suboxone — has emerged as the most-documented medication response. A clinical review described it as a promising option for both detoxification and longer-term maintenance in kratom-dependent patients, with clonidine, dihydrocodeine, and lofexidine mentioned as inpatient alternatives for people who can’t or don’t want to start buprenorphine ². Multiple case series have since reported patients successfully transitioned from kratom onto buprenorphine/naloxone maintenance, with dosing that ends up looking a lot like standard opioid-use-disorder dosing ^{5, 6}.

A case-based analysis tried to translate those reports into something more operational. The authors suggested that people using lower daily kratom doses may start on around 4/1 mg to 8/2 mg of buprenorphine/naloxone per day, while people using higher kratom doses may need 12/3 mg to 16/4 mg per day to feel steady ⁷. Those aren’t prescriptions — they’re patterns pulled from published cases. Your prescriber will land on your dose based on your history, your withdrawal severity, and how you respond in the first few days. The point is that this isn’t guesswork from scratch. There’s a starting map.

One more thing worth naming. Buprenorphine/naloxone has also been used successfully in kratom withdrawal when someone has serious concurrent pain — a case report described its use in a patient managing both kratom withdrawal and cancer pain, and it worked for both ⁹. That matters because many people using kratom heavily started with a pain problem that never got treated well. A medication that can address withdrawal and pain in the same conversation isn’t a small thing.

What the evidence doesn’t say is that everyone needs medication, or that buprenorphine is the only path. Some people stabilize with supportive care, comfort medications for symptoms, and structured therapy alone. Others need the medication piece to make everything else possible. This is a conversation to have with a clinician who knows the current literature, not a decision to make from a forum thread.

You might picture treatment as some blur of hospital hallways and forms. In reality, the first month has a shape to it, and knowing that shape can take some of the fear out of the phone call. Because kratom withdrawal tracks closely with opioid withdrawal, most programs borrow a familiar arc: get you medically safe, get you sleeping again, then start the harder work underneath ³.

1. Day one. You arrive. Someone takes a full history — what you’ve been using, how much, for how long, what else is in the picture (alcohol, benzodiazepines, prescribed medications, 7-OH). A clinician does a physical assessment and screens for the co-occurring stuff that so often rides along: depression, anxiety, PTSD, chronic pain. If you’re already in withdrawal, comfort measures start that day. If a medication conversation makes sense for you, it happens now, not later.

2. Days one through seven. This is the stabilization window. Withdrawal symptoms usually peak in the first 72 hours and then ease across the rest of the week ³. Sleep is often the last thing to come back. You’re monitored, hydrated, medicated when appropriate, and mostly left to rest between short check-ins. At Sunflower, biometric wearables track sleep quality, heart rate variability, and stress markers during this stretch, which gives the clinical team real numbers to adjust care against instead of guessing from how you say you feel.

3. Days eight through twenty-one. The therapy phase opens up as your nervous system settles. Individual sessions start looking at what kratom was doing for you — the pain it was numbing, the anxiety it was quieting, the trauma it was holding at arm’s length. Group work adds the piece isolation always steals: other people in the same fight. Family programming can start here too, if that’s part of your picture.

4. Days twenty-two through thirty. Discharge planning stops being an abstract idea. What’s your step-down look like — PHP, IOP, outpatient? Who’s your prescriber going forward if medication is part of the plan? What does week one at home actually include, hour by hour? The month doesn’t end with a graduation. It ends with a plan that has your name on it.

Here’s the part most kratom conversations skip. Almost nobody starts taking kratom because they’re bored. People start because something already hurt — a back injury that never quite healed, an anxiety that made mornings unbearable, a stretch of insomnia after a loss, old opioid cravings that came back uninvited, a trauma the body kept score of even when the mind tried to move on. Kratom worked, for a while. That’s the honest reason it’s hard to put down.

That’s where dual diagnosis care earns its name. A clinician looks at the depression, the PTSD, the panic, the chronic pain, the eating disorder that was in the background — and treats those as their own conditions, not as side notes to the substance use. Trauma-focused therapies like EMDR and cognitive processing therapy have their own bodies of evidence for what they treat. Pain gets a real plan, not a shrug. If medication for withdrawal is part of the picture, a case report has already shown buprenorphine/naloxone managing kratom withdrawal and significant pain in the same patient ⁹, which is the kind of integrated thinking this population needs.

You didn’t develop this problem in isolation. You won’t solve it in isolation either. The work underneath is where recovery actually holds.

Two safety realities sit alongside the addiction conversation, and they’re worth naming plainly. First, the product itself. When the FDA ran elemental analysis on kratom samples, they found heavy metals — vanadium, chromium, cobalt, nickel, arsenic, lead — in nearly every sample tested ¹². That doesn’t mean every bag on every shelf is contaminated. It means the market has no reliable quality floor, so what you’ve been putting in your body is not what any regulated medication would look like.

If you’re the one reading this because someone you love is buried in kratom or 7-OH, take a breath. You didn’t cause this, and you can’t willpower them out of it. What you can do is stay in the room, literally and figuratively, without turning every conversation into an ultimatum.

A few things that tend to help. Learn what withdrawal actually looks like so you’re not blindsided when they try to stop and get sick within hours — the symptoms track opioid withdrawal closely enough that medical support genuinely changes outcomes ³. Ask questions that don’t require a defense: How are you sleeping? What would make tomorrow easier? Keep naloxone in the house if there’s any chance other substances are in the mix; polysubstance risk is the real danger ¹⁷.

Don’t hand them a pamphlet and disappear. Offer to sit with them while they make the first call. Offer to drive them to the assessment. Small, specific, present. That’s what moves someone from stuck to starting.